Application of Artificial Intelligence in Early Detection of Eye Complications in Diabetics

NCT ID: NCT05655117

Last Updated: 2022-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

440 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-31

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this pragmatic trial is to test the benefit of using artificial intelligence-based eye screening i.e, a fundus camera device in the early detection of eye complications in diabetics. The main questions it aims to answer are:

To what extent does the application of artificial intelligence-based eye care at primary care clinics work well in achieving early detection of eye complications such as macular oedema? To what extent does the application of artificial intelligence-based eye care at primary care clinics work well in achieving early detection of eye complications such as retinopathy? Participants will be asked to participate in the screening for eye complications at primary care centres, and a fundus camera will be used for screening.

Researchers will compare the proportion of detected cases with early signs of eye complication among those using artificial intelligence-based eye screening i.e., fundus camera, to the proportion of detected cases among those using routine eye care clinics at the primary care centre.

Early detection of eye complications in diabetics prevents the risk of blindness.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the era of artificial inelegance(AI), a shift from tertiary to secondary and primary care when caring for a patient with diabetic retinopathy is highly recommended.

Due to low operation, AI could be used in the early detection and screening of diabetic retinopathy by application of the service across a mass population and resource-limited areas with a scarcity of eye care services.

AI-based eye care in terms of screening for diabetic retinopathy will make the screening process more effective and cheap and could be delegated to technicians, practitioners, and/or even home-based self-screening.

Recognizing the high prevalence of type 2 diabetes mellitus (T2DM) among adults, the use of a nonmydriatic fundus camera with AI is effective in eye exams as it improves adult adherence to eye screening.

The primary aim of the trial will be to assess the effectiveness of the application of AI devices in terms of fundus cameras in the early detection of diabetic retinopathy and macular oedema among diabetic patients attending primary care centres.

Research Questions:

To what extent does the application of artificial intelligence-based eye care at primary care centre is effective in achieving a high detection rate of macular oedema? To what extent does the application of artificial intelligence-based eye care at primary care clinic is effective in achieving a high detection rate of retinopathy?

General objective:

To estimate the effectiveness of applying AI-based eye care at primary care centres in achieving a high detection rate of macular oedema and retinopathy among diabetics.

Specific Objectives:

Aim 1: To compare the proportion of detected cases of macular oedema in the intervention versus the control group (routine eye care) attending the primary care centre.

Aim 2: To compare the proportion of detected cases of retinopathy in the intervention versus the control group (routine eye care) attending the primary care centre

Literature Review:

Although recent models had been suggested for implementing digital health solutions like stream fishing, inflow funnel, pyramid, and shuffling cards that represent options for clinical services with progressively increasing capacity and willingness to operationalize digital health.

However, various challenges are facing the deployment of AI, telehealth, and the internet of things (IoT) worldwide. Barriers to adopting these digital health solutions are many and could be inferred to infrastructure, the quality of the device, common willingness, and legal aspects.

Evidence revealed that using Macustat retina function scan AI in remote monitoring of a patient with age-related macular oedema or diabetic retinopathy has a great impact on patient health.

Research Design and Methods:

This is a six months clustered randomized trial that will recruit patients with type II diabetes who are attending primary eye care clinics at primary care centres in Hail city.

Participants (P):

The participants will be type II diabetic patients of both genders attending the selected primary care centres irrespective of their duration of disease and the types of medication currently received. The participants are expected to be adults aged 18 years and above. Children and young adults with juvenile diabetes mellitus will be excluded. In addition, severely ill patients, and patients with mental disorders will be excluded. The participants will be assessed at the start to collect the baseline data about diabetic retinopathy and macular oedema using AI devices to report detected cases. At the end of the trial, a similar report of detected cases will be obtained three and six months after the beginning of the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Artificial Intelegence Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus Macular Edema Due to Type 2 Diabetes Mellitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

AI Eye Screening in diabetics Diabetic retinopathy macular oedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AI-based screening for early detection of diabetic retinopathy and macular Oedema

The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre

Group Type EXPERIMENTAL

AI based eye screening

Intervention Type OTHER

The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre

Routine screening for diabetic retinopathy and macular oedema

The Routine screening for diabetic retinopathy and macular oedema in diabetics during a routine visit to an eye care clinic at the primary care centre.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AI based eye screening

The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetic patients aged 18-90

Exclusion Criteria

* Severely ill patient or patient with cancer
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Health Holding Company, Hail Health Cluster

UNKNOWN

Sponsor Role collaborator

The New Model of Care, Hail Health Cluster

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Khalil Alshammari, VIP Chief MO

Role: STUDY_CHAIR

Hail Health Cluster

Fakhralddin Elfakki, Researcher at MOC

Role: PRINCIPAL_INVESTIGATOR

New Model of Care, Hail Health Cluser

Meshari Aljamani, MOC Lead

Role: STUDY_DIRECTOR

New Model of Care, Hail Health Cluster

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fakhralddin Elfakki, Researcher at MOC

Role: CONTACT

Phone: +966530855161

Email: [email protected]

Marwa Mahmoud Mahdy, CSoC Lead

Role: CONTACT

Phone: +966508258235

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Model of Care Hail Cluster

Identifier Type: -

Identifier Source: org_study_id